□□□□□□□□

□□□□

□□□□□□□

- □□□□

- □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

- □□□□□□□□□□□□□□□□□□□□

- □□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□

[glossary_exclude]□□□□

1. European Medicines Agency (2002).*Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95)*.London:EMEA.Retrieved 12.08.2015 from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf[/glossary_exclude]

□□□□

A2-4.17-V1.1